Recombinant LAL Regulator Binding Sites for Polyketide Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for regulating polyketide and β-lactam compound production are inefficient, as they often rely on native LAL regulators that may not be optimally expressed or activated, leading to suboptimal production of these valuable compounds.
Innovation Solution
Engineering host cells to express recombinant LAL proteins with optimized binding sites, such as those with the sequence GGGGGT, to enhance the expression of polyketide synthases and β-lactam compound-producing proteins, thereby increasing production yields.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If native LAL regulators are used for compound production, then the system maintains natural regulation, but production efficiency is suboptimal due to inadequate expression or activation
Solution Approach 1:
The patent modifies the LAL regulator system by changing key parameters: introducing recombinant LAL proteins with optimized sequences, creating heterologous LAL binding sites with specific consensus sequences (e.g., GGGGGT), and adjusting promoter strength. These parameter changes enable constitutive or enhanced expression of LAL regulators, resolving the contradiction between maintaining natural regulation and achieving optimal production efficiency.
Solution Approach 2:
The patent introduces heterologous LAL binding sites as intermediary elements between the LAL regulator and the gene cluster promoter. These engineered binding sites with optimized sequences serve as mediators that enhance the interaction between LAL proteins and DNA, thereby improving transcriptional activation and compound production without disrupting the natural regulatory architecture.
2Productivity
If recombinant LAL proteins with optimized binding sites are introduced, then production yield increases, but system complexity increases
Solution Approach 1:
The patent creates universal LAL binding sites with consensus sequences that can function with multiple different LAL regulators and various gene clusters. The heterologous binding site design (e.g., containing GGGGGT motif) serves as a multi-functional element that can be applied across different polyketide and beta-lactam gene clusters, reducing the need for cluster-specific optimization and thereby managing complexity while enhancing productivity.
3Productivity
If LAL binding sites are engineered into the gene cluster, then transcription activation is enhanced, but genetic modification complexity increases
Solution Approach 1:
The patent simplifies genetic engineering by standardizing the LAL binding site sequence to a consensus motif (e.g., GGGGGT or extended versions like C1-T2-A3-G4-G5-G6-G7-G8-T9-T10-G11-C12). This parameter standardization allows for straightforward cloning and insertion of binding sites into target gene clusters, making the genetic modification process more accessible and easier to manufacture despite the enhancement in transcription activation.
Data Source
AI summary
The present disclosure provides nucleic acids encoding a Large ATP-binding regulator of the LuxR family (LAL) of transcription factors, vectors and host cells including such nucleic acids, and methods for producing compounds (e.g., polyketides or β-lactam compounds) with such nucleic acids, vectors, and/or host cells.